-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, Kangzhi Pharmaceutical announced that the company recently received a total of RMB 3.
5 million in government subsidies related to income, accounting for 10% of the company's net profit attributable to shareholders of listed companies in the latest audited fiscal year.
% or more
.
According to the "Accounting Standards for Business Enterprises No.
16 - Government Grants", the government grants related to assets refer to the government grants obtained by enterprises and used to purchase and construct or form long-term assets in other ways; government grants related to income , refers to government grants other than government grants related to assets
.
Since 2022, in addition to Kangzhi Pharmaceutical, a large number of pharmaceutical companies have announced that they have received subsidy "red envelopes", most of which are in the amount of one million yuan, and several companies have received more than 100 million yuan
.
For example, on April 22, Saisheng Pharmaceutical issued an announcement that the company recently received a government subsidy of 5.
12 million yuan.
The company stated that the above-mentioned government subsidy is expected to have a positive impact on the company's profit in 2022, and the final accounting treatment and the company's profit in 2022.
The impact is subject to the results confirmed by the auditor
.
On April 13, Shu Taishen announced that the company has recently received a notice that the company has recently obtained the “2021 Beijing High-tech Industry Development Fund Key Project” by the Beijing Municipal Bureau of Economy and Information Technology and the “National Key Project” by the Ministry of Science and Technology.
Government project funds for BDB-001 injection and other projects under the R&D Plan 2020 International Cooperation Project on Epidemic Response.
From January 1, 2022 to the date of disclosure of this announcement, the company and its wholly-owned subsidiaries have obtained government subsidies related to assets The capital is 10 million yuan, and the government subsidy funds related to the income are 3.
16 million yuan, with a total of 13.
16 million yuan
.
On April 8, Guangzhou Baiyunshan announced that the company and its subsidiaries have received various government subsidies of RMB 112 million from January 1, 2022 to March 31, 2022
.
Dongcheng Pharmaceutical issued an announcement on the evening of April 7 that its subsidiaries received government subsidies.
The government of Muping District, Yantai City will allocate 300 million yuan to support the company's integration of upstream and downstream pharmaceutical industry chains, technology introduction, and industrial investment in Yantai
.
On April 2, Boji Pharmaceutical announced that Jiangxi Bokang, a wholly-owned subsidiary of the company, recently received 4 million yuan in government subsidies related to income, accounting for 23.
55% of the company's audited net profit attributable to shareholders of listed companies in 2020.
%
.
Shuangcheng Pharmaceutical issued an announcement in February that the company and its holding subsidiary Ningbo Shuangcheng accumulated a total of RMB 6.
6865 million in government subsidy funds receivable or received related to income in the first twelve months
.
For another example, on February 7, Tianyao Co.
, Ltd.
announced that from May 28, 2021 to the date of this announcement, the company and its holding subsidiaries have received a total of about 25.
5227 million government subsidies, of which about 3.
1177 million yuan, accounting for 9.
18% of the company's audited net profit attributable to shareholders of listed companies in the most recent fiscal year; 22.
405 million yuan in government subsidies related to assets, accounting for 0.
75% of the company's audited net assets in the latest fiscal year
.
Behind the "red envelope rain" that a large number of pharmaceutical companies have received subsidies, it can be seen that the policy has strongly supported local pharmaceutical companies
.
In recent years, the rapid development of China's pharmaceutical industry is inseparable from the support of a series of favorable policies.
As pharmaceutical companies receive subsidies, it will help companies, especially innovative drug companies, to improve their independent innovation capabilities, and their scientific research strength will continue to increase.
Achieve new breakthroughs in other aspects
.
5 million in government subsidies related to income, accounting for 10% of the company's net profit attributable to shareholders of listed companies in the latest audited fiscal year.
% or more
.
According to the "Accounting Standards for Business Enterprises No.
16 - Government Grants", the government grants related to assets refer to the government grants obtained by enterprises and used to purchase and construct or form long-term assets in other ways; government grants related to income , refers to government grants other than government grants related to assets
.
Since 2022, in addition to Kangzhi Pharmaceutical, a large number of pharmaceutical companies have announced that they have received subsidy "red envelopes", most of which are in the amount of one million yuan, and several companies have received more than 100 million yuan
.
For example, on April 22, Saisheng Pharmaceutical issued an announcement that the company recently received a government subsidy of 5.
12 million yuan.
The company stated that the above-mentioned government subsidy is expected to have a positive impact on the company's profit in 2022, and the final accounting treatment and the company's profit in 2022.
The impact is subject to the results confirmed by the auditor
.
On April 13, Shu Taishen announced that the company has recently received a notice that the company has recently obtained the “2021 Beijing High-tech Industry Development Fund Key Project” by the Beijing Municipal Bureau of Economy and Information Technology and the “National Key Project” by the Ministry of Science and Technology.
Government project funds for BDB-001 injection and other projects under the R&D Plan 2020 International Cooperation Project on Epidemic Response.
From January 1, 2022 to the date of disclosure of this announcement, the company and its wholly-owned subsidiaries have obtained government subsidies related to assets The capital is 10 million yuan, and the government subsidy funds related to the income are 3.
16 million yuan, with a total of 13.
16 million yuan
.
On April 8, Guangzhou Baiyunshan announced that the company and its subsidiaries have received various government subsidies of RMB 112 million from January 1, 2022 to March 31, 2022
.
Dongcheng Pharmaceutical issued an announcement on the evening of April 7 that its subsidiaries received government subsidies.
The government of Muping District, Yantai City will allocate 300 million yuan to support the company's integration of upstream and downstream pharmaceutical industry chains, technology introduction, and industrial investment in Yantai
.
On April 2, Boji Pharmaceutical announced that Jiangxi Bokang, a wholly-owned subsidiary of the company, recently received 4 million yuan in government subsidies related to income, accounting for 23.
55% of the company's audited net profit attributable to shareholders of listed companies in 2020.
%
.
Shuangcheng Pharmaceutical issued an announcement in February that the company and its holding subsidiary Ningbo Shuangcheng accumulated a total of RMB 6.
6865 million in government subsidy funds receivable or received related to income in the first twelve months
.
For another example, on February 7, Tianyao Co.
, Ltd.
announced that from May 28, 2021 to the date of this announcement, the company and its holding subsidiaries have received a total of about 25.
5227 million government subsidies, of which about 3.
1177 million yuan, accounting for 9.
18% of the company's audited net profit attributable to shareholders of listed companies in the most recent fiscal year; 22.
405 million yuan in government subsidies related to assets, accounting for 0.
75% of the company's audited net assets in the latest fiscal year
.
Behind the "red envelope rain" that a large number of pharmaceutical companies have received subsidies, it can be seen that the policy has strongly supported local pharmaceutical companies
.
In recent years, the rapid development of China's pharmaceutical industry is inseparable from the support of a series of favorable policies.
As pharmaceutical companies receive subsidies, it will help companies, especially innovative drug companies, to improve their independent innovation capabilities, and their scientific research strength will continue to increase.
Achieve new breakthroughs in other aspects
.
